Patient must not have received any prior marrow-ablative chemotherapy and autologous hematopoietic cell transplant
Ineligible for hematopoietic stem cell transplant.
Hematopoietic stem cell transplant =< 3 months prior to registration
No prior hematopoietic transplant
Prior hematopoietic transplant
relapse within 1 year from frontline chemo-immunotherapy and ineligible for autologous hematopoietic stem cell transplant (auto-HSCT)
History of organ or hematopoietic stem cell transplant.
relapse within 1 year from frontline chemo-immunotherapy and ineligible for autologous hematopoietic stem cell transplant (auto-HSCT)
Has received prior autologous hematopoietic stem cell transplant within the last 60 days
Prior hematopoietic stem cell transplant for AML
Be a recipient of hematopoietic stem cell transplant.
Patients who are hematopoietic stem cell transplant candidates are excluded
Prior hematopoietic stem cell transplant for the diagnosis of MDS
Hodgkin's disease (HD): Induction failures, after first complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant), or those with active disease
Patient must be ? 3 months from hematopoietic stem cell transplant, must not have active GVHD, and must be off all immunosuppression
Patients must not have a prior autologous, syngeneic or allogeneic hematopoietic stem cell transplant
Received a hematopoietic stem cell transplant within the previous 2 months
Stem cells: patients must have an autologous hematopoietic stem cell product cryopreserved and available for re-infusion after 131I-8H9 treatment; the minimum dose for hematopoietic stem cells is 2 x 10^6 cluster of differentiation (CD)34+ cells/kg
Stem cells from an identical donor could be used for autologous hematopoietic cell transplant (HCT)
Prior hematopoietic cell transplant: must be >= 3 months after previous transplant
History of, or scheduled, hematopoietic stem cell transplant within 24 weeks of Screening
Hodgkin's disease (HD): induction failures, second or third complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant)
Prior hematopoietic stem cell transplant
The subject must be a recipient of hematopoietic stem cell or solid organ transplant.
Hematopoietic cell transplant-co-morbidity Index greater than 2
Has no other hematopoietic stem cell transplant of any type prior to the current planned autologous hematopoietic cell transplant
Has received any type of hematopoietic cell transplant
Prior allogeneic or autologous hematopoietic stem cell transplant in the last 6 months
Prior history of hematopoietic stem cell transplant
Unless approved by the medical monitor, may not have received autologous hematopoietic stem cell transplant within 3 months before treatment
Prior hematopoietic stem cell transplant.
Considered eligible for hematopoietic stem cell transplant (allogeneic or autologous) at the time of signing the ICF.
History of hematopoietic stem cell transplant
Prior allogeneic hematopoietic stem-cell transplant for participants with DLBCL, FL, MCL, and CLL only. Prior allogenic hematopoietic stem-cell transplant is permitted for participants with ALL
Received autologous hematopoietic stem cell transplant within the last 3 months
Prior autologous hematopoietic stem cell transplant ? 3 months.
Newly diagnosed, symptomatic multiple myeloma patients for whom treatment is indicated per the NCCN guidelines, and for whom a hematopoietic stem cell transplant is not planned or scheduled during the study or are considered ineligible for hematopoietic stem cell transplant, with measurable disease
Received a hematopoietic stem cell transplant
Non-Hodgkin's lymphoma - induction failures, second or third complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant)
Hodgkin's disease - induction failure, second or later complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant)
Hodgkin's disease (HD): induction failures, second or third complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant); or
Prior autologous hematopoietic stem cell transplant
Prior hematopoietic stem cell transplant
Prior autologous hematopoietic stem cell transplant within 90 days of study entry
Autologous hematopoietic stem cell transplant or fludarabine chemotherapy within 6 months of study enrollment
Transformed lymphoma is included if patients are ineligible for (or refuse) hematopoietic stem cell transplant
Has not received a prior hematopoietic stem cell transplant within the previous 3 months
Patients who are candidates for hematopoietic stem cell transplant
Prior treatment with hematopoietic stem cell transplant
Prior autologous hematopoietic stem cell infusion <4 weeks prior to first study dose
Prior autologous or allogeneic hematopoietic stem cell transplant
Hematopoietic stem cell transplant recipient within 100 days post-transplant
Patients must have received allogeneic hematopoietic stem cell transplant and be greater than 30 days post-transplant at the time of registration
Prior allogeneic hematopoietic stem cell transplantation; (patients may have received a prior autologous hematopoietic stem cell transplant)
Scheduled to undergo either autologous or allogeneic hematopoietic stem cell transplant
Prior autologous or allogeneic hematopoietic stem cell transplant
Planned post-transplant maintenance therapy except for FLT3 inhibitors or TKIs must be declared prior to randomization. If it is known prior to enrollment that the hematopoietic stem cell product will need to be cryopreserved, the patient should not be enrolled.
Between 12 and 60 months after completion of cancer therapy (chemotherapy, radiation, hematopoietic cell transplant [HCT])
Prior allogeneic or autologous hematopoietic stem cell transplant in past 12 months
Autologous hematopoietic stem cell transplant < 3 months prior to enrollment.
Patients with prior autologous hematopoietic stem cell transplant who, in the investigator's judgment, have not fully recovered from the effects of the last transplant (e.g., transplant related side effects).
